Together, these studies comprehensively define the KRASi-induced proteome and identify ALPP/ALPPL2 as a promising cell surface target for combination with KRASi to enhance response and forestall KRASi resistance.
Jonathan M. DeLiberty, Fan-Yi Kong, Qi-Jia Yu et al.· bioRxiv· 0 citations
Direct inhibition of oncogenic RAS has emerged as a clinically active therapeutic strategy for RAS-addicted cancers, including pancreatic ductal adenocarcinoma (PDAC). However, resistance is likely to limit the durability of therapeutic response, motivating combination strategies that target adaptive survival mechani...
Joshua H. Choe, Kyle J. Seamon, Julien Dilly et al.· Cancer Research· 0 citations
The adaptive response to KRASG12C inhibitors (KRASi) in KRASG12C-mutant lung adenocarcinoma models is profile using an integrated genetic, transcriptomic, and mass-spectrometry-based quantitative temporal proteomic platform.
A. Padhye, Kalisa Kang, Fan-Yi Kong et al.· bioRxiv· 0 citations
These studies establish a comprehensive proteomic resource for the PDAC/KRASi research community and identify ALPP/ALPPL2 as a promising cell surface target for combination with KRASi to drive deeper, sustained responses and prevent or forestall KRASi resistance.
Jonathan M. DeLiberty, Fan-Yi Kong, Qi-Jia Yu et al.· Cancer Research· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.